ABS — Arctic Bioscience AS Income Statement
0.000.00%
- NOK116.95m
- NOK85.97m
- NOK33.75m
- 33
- 35
- 21
- 16
Annual income statement for Arctic Bioscience AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | NAS | NAS | NAS | NAS | NAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 30 | 20.5 | 21.5 | 34.3 | 33.8 |
Cost of Revenue | |||||
Gross Profit | 12.2 | 5.31 | 5.16 | 11.6 | 9.77 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 33.1 | 42.2 | 62.1 | 71.7 | 82.3 |
Operating Profit | -3.08 | -21.7 | -40.6 | -37.4 | -48.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.99 | -22.6 | -42.6 | -34 | -45.5 |
Net Income After Taxes | -3.99 | -22.6 | -42.6 | -34 | -45.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.99 | -22.6 | -42.6 | -34 | -45.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.99 | -22.6 | -42.6 | -34 | -45.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.164 | -0.89 | -1.67 | -1.28 | -1.77 |
Dividends per Share |